NTT
NTT Ltd. , a leading IT infrastructure and services company, is using technology and innovation to equally enhance the fan experience across both the Tour de France and the Tour de France Femmes avec Zwift.
The 2022 event will see the inaugural women’s race which will start on the Champs-Élysées on July 24th 2022, prior to the conclusion of the men’s race on the same day. The women’s race will feature 24 teams of six riders and will conclude on July 31st 2022 in La Super Planche des Belles Filles. NTT has been the official technology partner of the Tour de France for the past eight years.
For the first time ever, and at a time when interest in women’s cycling is on the rise, NTT will bring fans closer to the action and shine a light on this notable occasion through the implementation of real-time tracking of the riders, the Race Center and its predictive modelling strategy to support the race. The model also includes @letourdata , the data-driven content channel that helps tell the race’s stories over social media and broadcast. Rider and team profiles will uncover unique insights into the women’s pro peloton.
In addition to this, NTT alongside A.S.O. will deliver a host of new and enhanced digital experiences to engage fans around the world, both at home and along the roadside. These experiences include:
- The Digital Human: NTT has developed an interactive kiosk featuring an AI-generated realistic human avatar, trained on the relevant race and tourist information. This technology will be deployed at the official fan store at the Grand Depart in Copenhagen and in NTT’s Technical Truck at the end of every stage.
- An enhanced digital twin : Last year, NTT created a digital twin of the event, which enabled staff to gain real-time visibility and ultimately streamline operations to ensure the continuity and resilience of the race. This year, the technology has enhanced connectivity to provide smarter event operations, enabling quicker, more informed decisions in a highly complex and ever-changing environment.
- Strava partnership: NTT’s live storytelling channel, @letourdata, in collaboration with Strava, will be bringing real-time comparisons between amateurs, pros, and King of the Mountain (or fastest known times) to social media and broadcast during the race.
“With female cycling on the rise as we saw through the 2020 edition of La Course by Le Tour de France avec FDJ with over 30 million TV audience viewers, we’re incredibly proud to continue to help widen the fan base and be part of this historic milestone for female cycling. There is still much more work to be done to achieve equality in cycling, but we’re extremely passionate about doing what we can to increase the accessibility of the sport. Our technology means we can bring the action to more fans than ever before,” says Michele McGuire, Vice President of Managed Services Delivery, Europe at NTT Ltd.
“When it comes to the technology, both races are highly dynamic and require access to real-time information to ensure continuous and smooth operations while creating more informed and engaged fans. NTT’s full stack of solutions and expertise will continue to support the A.S.O. in transforming the famous race,” McGuire adds.
“At A.S.O., we’re extremely proud to be launching Tour de France Femmes avec Zwift and to be able to count on key technical partners such as NTT. Our partnership with NTT is well known for bringing the fans closer to the action. 2022 marks a momentous occasion for women’s cycling, and fans around the world are extremely excited to witness the first edition of the Tour de France Femmes avec Zwift,” said Julien Goupil, Media & Partnerships Director at A.S.O..
NTT’s role as the official technology partner to Tour de France Femmes avec Zwift, means NTT will now support A.S.O. at four of its female events, including Paris-Roubaix Femmes avec Zwift, Flèche Wallonne Femmes, and Liège-Bastogne-Liège Femmes. To find out more about how NTT supports A.S.O., visit: https://services.global.ntt/tourdefrance
Follow @letourdata on Twitter and look for NTT’s race predictions using #NTTPredictor.
ENDS
About Amaury Sport Organisation
Amaury Sport Organisation is a company that owns, designs and organises top international sporting events. Specialised in the ‘non-stadia’ events, it has in-house knowledge of professions linked to organisation, media and sales of sports events. A.S.O. organises 250 days of competition per year, with 90 events in 30 countries. A.S.O. is involved in 5 major sports including cycling with the Tour de France, motor sports with the Dakar, mass events with the Schneider Electric Marathon de Paris, golf with the Lacoste Ladies Open de France and sailing with production and distribution of images for prestigious races. Amaury Sport Organisation is a subsidiary of the Amaury Group, media and sport group that owns the newspaper L’Équipe.
About NTT Ltd.
NTT Ltd. is a leading IT infrastructure and services company. With revenues of over USD 10 billion, we operate in more than 200 countries and regions, and serve 5,000 clients across multiple industries. Through technology and innovation, we deliver a secure and connected future that empowers our people, clients and communities. We lay the foundation for organizations’ edge-to-cloud networking ecosystem, simplify the complexity of their workloads across multicloud environments, and innovate at the edge of their IT environments, where networks, cloud and applications converge. On the journey towards a software-defined future, we support organizations with platform-delivered infrastructure services. As part of the global NTT Corporation, we serve 65% of the Fortune Global 500 and 80% of the Fortune Global 100. We enable a connected future.
Visit us at services.global.ntt
View source version on businesswire.com: https://www.businesswire.com/news/home/20220627005681/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom